Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide has rapidly gained interest as a broader cardiometabolic intervention. This narrat...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2026-06-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Acceso en liña: | https://doi.org/10.1177/11795468261460202 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|